N-Methyl-d-aspartate (NMDA) receptor function and excitotoxicity in Huntington's disease

Progress in Neurobiology

Volumn 81, Issue 5-6, 2007, Pages 272-293

  Fan, Mannie M Y ^a   Raymond, Lynn A ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

Excitotoxicity; Huntingtin; Huntington's disease; N Methyl d aspartate receptors

Indexed keywords

AMANTADINE; CASPASE; CREATINE; ICOSAPENTAENOIC ACID ETHYL ESTER; KETAMINE; MEMANTINE; MILACEMIDE; MINOCYCLINE; MIRAXION; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; PLACEBO; POSTSYNAPTIC DENSITY PROTEIN 95; REMACEMIDE; RILUZOLE; UBIDECARENONE; UNCLASSIFIED DRUG;

CALCIUM HOMEOSTASIS; CLINICAL TRIAL; DISORDERS OF MITOCHONDRIAL FUNCTIONS; DRUG MEGADOSE; ENZYME ACTIVATION; EXCITOTOXICITY; GENETIC VARIABILITY; HUMAN; HUNTINGTON CHOREA; HYPOTHESIS; MEMBRANE DEPOLARIZATION; MITOCHONDRIAL MEMBRANE; MODEL; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; PROTEIN STRUCTURE; REVIEW; SIGNAL TRANSDUCTION;

ANIMALS; DISEASE MODELS, ANIMAL; EXCITATORY AMINO ACIDS; HUMANS; HUNTINGTON DISEASE; NEURONS; RECEPTORS, N-METHYL-D-ASPARTATE;

EID: 34047100940     PISSN: 03010082     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pneurobio.2006.11.003     Document Type: Review

References (242)

1. Akazawa C., Shigemoto R., Bessho Y., Nakanishi S., and Mizuno N. Differential expression of five N-methyl-d-aspartate receptor subunit mRNAs in the cerebellum of developing and adult rats. J. Comp. Neurol. 347 (1994) 150-160
2. Albin R.L., Young A.B., Penney J.B., Handelin B., Balfour R., Anderson K.D., Markel D.S., Tourtellotte W.W., and Reiner A. Abnormalities of striatal projection neurons and N-methyl-d-aspartate receptors in presymptomatic Huntington's disease. N. Engl. J. Med. 322 (1990) 1293-1298
3. Albin R.L., Reiner A., Anderson K.D., Dure IV L.S., Handelin B., Balfour R., Whetsell Jr. W.O., Penney J.B., and Young A.B. Preferential loss of striato-external pallidal projection neurons in presymptomatic Huntington's disease. Ann. Neurol. 31 (1992) 425-430
4. Ali N.J., and Levine M.S. Changes in expression of N-methyl-d-aspartate receptor subunits occur early in the R6/2 mouse model of Huntington's disease. Dev. Neurosci. 28 (2006) 230-238
5. Andre V.M., Cepeda C., Venegas A., Gomez Y., and Levine M.S. Altered cortical glutamate receptor function in the R6/2 model of Huntington's disease. J. Neurophysiol. 95 (2006) 2108-2119
6. Arenas J., Campos Y., Ribacoba R., Martin M.A., Rubio J.C., Ablanedo P., and Cabello A. Complex I defect in muscle from patients with Huntington's disease. Ann. Neurol. 43 (1998) 397-400
7. Ariano M.A., Wagle N., and Grissell A.E. Neuronal vulnerability in mouse models of Huntington's disease: membrane channel protein changes. J. Neurosci. Res. 80 (2005) 634-645
8. Arning L., Kraus P.H., Valentin S., Saft C., Andrich J., and Epplen J.T. NR2A and NR2B receptor gene variations modify age at onset in Huntington disease. Neurogenetics 6 (2005) 25-28
9. Aronin N., Chase K., Young C., Sapp E., Schwarz C., Matta N., Kornreich R., Landwehrmeyer B., Bird E., Beal M.F., Vonsattel J.P., Smith T., Carraway R., Boyce F.M., Young A.B., Penney J.B., and DiFiglia M. CAG expansion affects the expression of mutant huntingtin in the Huntington's disease brain. Neuron 15 (1995) 1193-1201
10. Arzberger T., Krampfl K., Leimgruber S., and Weindl A. Changes of NMDA receptor subunit (NR1, NR2B) and glutamate transporter (GLT1) mRNA expression in Huntington's disease-an in situ hybridization study. J. Neuropathol. Exp. Neurol. 56 (1997) 440-454
11. Asztely F., and Gustafsson B. Ionotropic glutamate receptors: their role in the expression of hippocampal synaptic plasticity. Mol. Neurobiol. 12 (1996) 1-11
12. Barria A., and Malinow R. Subunit-specific NMDA receptor trafficking to synapses. Neuron 35 (2002) 345-353
13. Bartlett T.E., Bannister N.J., Collett V.J., Dargan S.L., Massey P.V., Bortolotto Z.A., Fitzjohn S.M., Bashir Z.I., Collingridge G.L., and Lodge D. Differential roles of NR2A and NR2B-containing NMDA receptors in LTP and LTD in the CA1 region of 2-week old rat hippocampus. Neuropharmacology (2006) (Epub ahead of print)
14. Beal M.F. Aging, energy, and oxidative stress in neurodegenerative diseases. Ann. Neurol. 38 (1995) 357-366
15. Beal M.F. Mitochondria take center stage in aging and neurodegeneration. Ann. Neurol. 58 (2005) 495-505
16. Beal M.F., Kowall N.W., Ellison D.W., Mazurek M.F., Swartz K.J., and Martin J.B. Replication of neurochemical characteristics of Huntington's disease by quinolinic acid. Nature 321 (1986) 168-171
17. Beal M.F., Ferrante R.J., Swartz K.J., and Kowall N.W. Chronic quinolinic acid lesions in rats closely resemble Huntington's disease. J. Neurosci. 11 (1991) 1649-1659
18. Beal M.F., Brouillet E., Jenkins B.G., Ferrante R.J., Kowall N.W., Miller J.M., Storey E., Srivastava R., Rosen B.R., and Hyman B.T. Neurochemical and histologic characterization of striatal excitotoxic lesions produced by the mitochondrial toxin 3-nitopropionic acid. J. Neurosci. 13 (1993) 4181-4192
19. Behrens P.F., Franz P., Woodman B., Lindenberg K.S., and Landwehrmeyer G.B. Impaired glutamate transport and glutamate-glutamine cycling: downstream effects of the Huntington mutation. Brain 125 (2002) 1908-1922
20. Beister A., Kraus P., Kuhn W., Dose M., Weindl A., and Gerlach M. The N-methyl-d-aspartate antagonist memantine retards progression of Huntington's disease. J. Neural Transm. Suppl. 68 (2004) 117-122
21. Berberich S., Punnakkal P., Jensen V., Pawlak V., Seeburg P.H., Hvalby O., and Kohr G. Lack of NMDA receptor subtype selectivity for hippocampal long-term potentiation. J. Neurosci. 25 (2005) 6907-6910
22. Berberich S., Jensen V., Hvalby O., Seeburg P.H., and Kohr G. The role of NMDAR subtypes and charge transfer during hippocampal LTP induction. Neuropharmacology (2006) (Epub ahead of print)
23. 2+ signals and death programmes in neurons. Philos. Trans. R. Soc. Lond. B Biol. Sci. 360 (2005) 2255-2258
24. Biziere K., and Coyle J.T. Effects of cortical ablation on the neurotoxicity and receptor binding of kainic acid in the striatum. J. Neurosci. Res. 4 (1979) 383-398
25. Bogdanov M.B., Ferrante R.J., Kuemmerle S., Klivenyi P., and Beal M.F. Increased vulnerability to 3-nitropropionic acid in an animal model of Huntington's disease. J. Neurochem. 71 (1998) 2642-2644
26. Bonelli R.M., Heuberger C., and Reisecker F. Minocycline for Huntington's disease: an open label study. Neurology 60 (2003) 883-884
27. Bonelli R.M., Hodl A.K., Hofmann P., and Kapfhammer H.P. Neuroprotection in Huntington's disease: a 2-year study on minocycline. Int. Clin. Psychopharmacol. 19 (2004) 337-342
28. Bonelli R.M., Wenning G.K., and Kapfhammer H.P. Huntington's disease: present treatments and future therapeutic modalities. Int. Clin. Psychopharmacol. 19 (2004) 51-62
29. Bonelli R.M., and Wenning G.K. Pharmacological management of Huntington's disease: an evidence-based review. Curr. Pharm. Des. 12 (2006) 2701-2720
30. Brennan Jr. W.A., Bird E.D., and Aprille J.R. Regional mitochondrial respiratory activity in Huntington's disease brain. J. Neurochem. 44 (1985) 1948-1950
31. Brinkman R.R., Mezei M.M., Theilmann J., Almqvist E., and Hayden M.R. The likelihood of being affected with Huntington disease by a particular age, for a specific CAG size. Am. J. Hum. Genet. 60 (1997) 1202-1210
32. Brouillet E., Hantraye P., Ferrante R.J., Dolan R., Leroy-Willig A., Kowall N.W., and Beal M.F. Chronic mitochondrial energy impairment produces selective striatal degeneration and abnormal choreiform movements in primates. Proc. Natl. Acad. Sci. U.S.A. 92 (1995) 7105-7109
33. Browne S.E., Bowling A.C., MacGarvey U., Baik M.J., Berger S.C., Muqit M.M., Bird E.D., and Beal M.F. Oxidative damage and metabolic dysfunction in Huntington's disease: selective vulnerability of the basal ganglia. Ann. Neurol. 41 (1997) 646-653
34. Brustovetsky N., Brustovetsky T., Purl K.J., Capano M., Crompton M., and Dubinsky J.M. Increased susceptibility of striatal mitochondria to calcium-induced permeability transition. J. Neurosci. 23 (2003) 4858-4867
35. Brustovetsky N., LaFrance R., Purl K.J., Brustovetsky T., Keene C.D., Low W.C., and Dubinsky J.M. Age-dependent changes in the calcium sensitivity of striatal mitochondria in mouse models of Huntington's disease. J. Neurochem. 93 (2005) 1361-1370
36. Cepeda C., Ariano M.A., Calvert C.R., Flores-Hernandez J., Chandler S.H., Leavitt B.R., Hayden M.R., and Levine M.S. NMDA receptor function in mouse models of Huntington disease. J. Neurosci. Res. 66 (2001) 525-539
37. Cepeda C., Itri J.N., Flores-Hernandez J., Hurst R.S., Calvert C.R., and Levine M.S. Differential sensitivity of medium- and large-sized striatal neurons to NMDA but not kainate receptor activation in the rat. Eur. J. Neurosci. 14 (2001) 1577-1589
38. Cepeda C., Hurst R.S., Calvert C.R., Hernandez-Echeagaray E., Nguyen O.K., Jocoy E., Christian L.J., Ariano M.A., and Levine M.S. Transient and progressive electrophysiological alterations in the corticostriatal pathway in a mouse model of Huntington's disease. J. Neurosci. 23 (2003) 961-969
39. Cha J.-H.J., Frey A.S., Alsdorf S.A., Kerner J.A., Kosinski C.M., Mangiarini L., Penney Jr. J.B., Davies S.W., Bates G.P., and Young A.B. Altered neurotransmitter receptor expression in transgenic mouse models of Huntington's disease. Philos. Trans. R. Soc. Lond. B 354 (1999) 981-989
40. 2+ block of NMDA-receptor channels as a mechanism of modulation. Nature 356 (1992) 521-523
41. Chen N., Luo T., and Raymond L.A. Subtype-dependence of NMDA receptor channel open probability. J. Neurosci. 19 (1999) 6844-6854
42. Chen N., Luo T., Wellington C., Metzler M., McCutcheon K., Hayden M.R., and Raymond L.A. Subtype-specific enhancement of NMDA receptor currents by mutant huntingtin. J. Neurochem. 72 (1999) 1890-1898
43. Choo Y.S., Johnson G.V., MacDonald M., Detloff P.J., and Lesort M. Mutant huntingtin directly increases susceptibility of mitochondria to the calcium-induced permeability transition and cytochrome c release. Hum. Mol. Genet. 13 (2004) 1407-1420
44. Christie J.M., Jane D.E., and Monaghan D.T. Native N-methyl-d-aspartate receptors containing NR2A and NR2B subunits have pharmacologically distinct competitive antagonist binding sites. J. Pharmacol. Exp. Ther. 292 (2000) 1169-1174
45. Conn P.J., and Pin J.P. Pharmacology and functions of metabotropic glutamate receptors. Annu. Rev. Pharmacol. Toxicol. 37 (1997) 205-237
46. Cowan, C.M., Hayden, M.R., Raymond, L.A., 2005. Effect of mutant huntingtin on NMDA receptor phosphorylation. Society for Neuroscience 35th Annual Meeting. Program # 90.8.
47. Coyle J.T., and Schwarcz R. Lesion of striatal neurons with kainic acid provides a model for Huntington's chorea. Nature 263 (1976) 244-246
48. Cramer H., Warter J.M., and Renaud B. Analysis of neurotransmitter metabolites and adenosine 3′,5′-monophosphate in the CSF of patients with extrapyramidal motor disorders. Adv. Neurol. 40 (1984) 431-435
49. Cull-Candy S., Brickley S., and Farrant M. NMDA receptor subunits: diversity, development and disease. Curr. Opin. Neurobiol. 11 (2001) 327-335
50. Cybulska-Klosowicz A., Mazarakis N.K., Van Dellen A., Blakemore C., Hannan A.J., and Kossut M. Impaired learning-dependent cortical plasticity in Huntington's disease transgenic mice. Neurobiol. Dis. 17 (2004) 427-434
51. Dalbem A., Silveira C.V., Pedroso M.F., Breda R.V., Werne Baes C.V., Bartmann A.P., and da Costa J.C. Altered distribution of striatal activity-dependent synaptic plasticity in the 3-nitropropionic acid model of Huntington's disease. Brain Res. 1047 (2005) 148-158
52. Davies S., and Ramsden D.B. Huntington's disease. J. Clin. Pathol.: Mol. Pathol. 54 (2001) 409-413
53. DiFiglia M. Excitotoxic injury of the neostriatum: a model for Huntington's disease. Trends Neurosci. 13 (1990) 286-289
54. Dingledine R., Borges K., Bowie D., and Traynelis S.F. The glutamate receptor ion channels. Pharmacol. Rev. 51 (1999) 7-61
55. Dragunow M., Faull R.L., Lawlor P., Beiharz E.J., Singleton K., Walker E.B., and Mee E. In situ evidence for DNA fragmentation in Huntington's disease striatum and Alzheimer's disease temporal lobes. Neuroreport 6 (1995) 1053-1057
56. Duchen M.R. Roles of mitochondria in health and disease. Diabetes 53 (2004) S96-S102
57. Dugan L.L., Sensi S.L., Canzoniero L.M., Handran S.D., Rothman S.M., Lin T.S., Goldberg M.P., and Choi D.W. Mitochondrial production of reactive oxygen species in cortical neurons following exposure to N-methyl-d-aspartate. J. Neurosci. 15 (1995) 63777-63788
58. Edwardson J.M., Wang C.T., Gong B., Wyttenbach A., Bai J., Jackson M.B., Chapman E.R., and Morton A.J. Expression of mutant huntingtin blocks exocytosis in PC12 cells by depletion of complexin II. J. Biol. Chem. 278 (2003) 30849-30853
59. Engelsen B. Neurotransmitter glutamate: its clinical importance. Acta Neurol. Scand. 74 (1986) 337-355
60. Erreger K., Dravid S.M., Banke T.G., Wyllie D.J., and Traynelis S.F. Subunit-specific gating controls rat NR1/NR2A and NR1/NR2B NMDA channel kinetics and synaptic signaling profiles. J. Physiol. 563 (2005) 345-358
61. Fan, M.M.Y., Fernandes, H.B., Zhang, L.Y.J., Hayden, M.R., Raymond, L.A., Altered NMDA receptor trafficking in a YAC transgenic mouse model of Huntington's disesase, submitted for publication.
62. Ferrante R.J., Kowall N.W., Beal M.F., Richardson Jr. E.P., Bird E.D., and Martin J.B. Selective sparing of a class of striatal neurons in Huntington's disease. Science 230 (1985) 561-563
63. Ferrante R.J., Kowall N.W., Beal M.F., Martin J.B., Bird E.D., and Richardson Jr. E.P. Morphologic and histochemical characteristics of a spared subset of striatal neurons in Huntington's disease. J. Neuropathol. Exp. Neurol. 46 (1987) 12-27
64. Ferrante R.J., Kowall N.W., Cipolloni P.B., Storey E., and Beal M.F. Excitotoxin lesions in primates as a model for Huntington's disease: histopathologic and neurochemical characterization. Exp. Neurol. 119 (1993) 46-71
65. Gerber G., Kangrga I., Ryu P.D., Larew J.S., and Randic M. Multiple effects of phorbol esters in the rat spinal dorsal horn. J. Neurosci. 9 (1989) 3606-3617
66. Ghasemzadeh M.B., Sharma S., Surmeier D.J., Eberwine J.H., and Chesselet M.F. Multiplicitiy of glutamate receptor subunits in single striatal neurons: an RNA amplification study. Mol. Pharmacol. 49 (1996) 852-859
67. Gines S., Seong I.S., Fossale E., Ivanova E., Trettel F., Gusella J.F., Wheeler V.C., Persichetti F., and MacDonald M.E. Specific progressive cAMP reduction implicates energy deficit in presymptomatic Huntington's disease knock-in mice. Hum. Mol. Genet. 12 (2003) 497-508
68. Gingrich J.R., Pelkey K.A., Fam S.R., Huang Y., Petralia R.S., Wenthold R.J., and Salter M.W. Unique domain anchoring of Src to synaptic NMDA receptors via the mitochondrial protein NADH dehydrogenase subunit 2. Proc. Natl. Acad. Sci. U.S.A. 101 (2004) 6237-6242
69. Giorgini F., and Muchowski P.J. Connecting the dots in Huntington's disease with protein interaction networks. Genome Biol. 6 (2005) 210
70. Giuffra M.E., Mouradian M.M., and Chase T.N. Glutamatergic therapy of Huntington's chorea. Clin. Neuropharmacol. 15 (1992) 148-151
71. Goehler H., Lalowski M., Stelzl U., Waelter S., Stroedicke M., Worm U., Droege A., Lindenberg K.S., Knoblich M., Haenig C., Herbst M., Suopanki J., Scherzinger E., Abraham C., Bauer B., Hasenbank R., Fritzsche A., Ludewig A.H., Bussow K., Coleman S.H., Gutekunst C.A., Landwehrmeyer B.G., Lehrach H., and Wanker E.E. A protein interaction network links GIT1, an enhancer of huntingtin aggregation, to Huntington's disease. Mol. Cell. 15 (2004) 853-865
72. Graham R.K., Deng Y., Slow E.J., Haigh B., Bissada N., Lu G., Pearson J., Shehadeh J., Bertram L., Murphy Z., Warby S.C., Doty C.N., Roy S., Wellington C.L., Leavitt B.R., Raymond L.A., Nicholson D.W., and Hayden M.R. Cleavage at the caspase-6 site is required for neuronal dysfunction and degeneration due to mutant huntingtin. Cell 125 (2006) 1179-1191
73. Graveland G.A., Williams R.S., and DiFiglia M. Evidence for degenerative and regenerative changes in neostriatal spiny neurons in Huntington's disease. Science 227 (1985) 770-773
74. Greene J.G., and Greenamyre J.T. Characterization of the excitotoxic potential of the reversible succinate dehydrogenase inhibitor malonate. J. Neurochem. 64 (1995) 430-436
75. Greene J.G., Porter R.H., Eller R.V., and Greenamyre J.T. Inhibition of succinate dehydrogenase by malonic acid produces and "excitotoxic" lesion in rat striatum. J. Neurochem. 61 (1993) 1151-1154
76. Gu M., Gash M.T., Mann V.M., Javoy-Agid F., Cooper J.M., and Schapira A.H. Mitochondrial defect in Huntington's disease caudate nucleus. Ann. Neurol. 39 (1996) 385-389
77. Guidetti P., Luthi-Carter R.E., Augood S.J., and Schwarcz R. Neostriatal and cortical quinolinate levels are increased in early grade Huntington's disease. Neurobiol. Dis. 17 (2004) 455-461
78. Guidetti P., Bates G.P., Graham R.K., Hayden M.R., Leavitt B.R., MacDonald M.E., Slow E.J., Wheeler V.C., Woodman B., and Schwarcz R. Elevated brain 3-hydroxykynurenine and quinolinate levels in Huntington disease mice. Neurobiol. Dis. 23 (2006) 190-197
79. Gusella J.F., and MacDonald M.E. Molecular genetics: unmasking polyglutamine triggers in neurodegenerative disease. Nat. Rev. 1 (2000) 109-115
80. Gutekunst C.A., Li S.H., Yi H., Ferrante R.J., Li X.J., and Hersch S.M. The cellular and subcellular localization of huntingtin-associated protein 1 (HAP1): comparison with huntingtin in rat and human. J. Neurosci. 18 (1998) 7674-7686
81. Handley O.J., Naji J.J., Dunnett S.B., and Rosser A.E. Pharmaceutical, cellular and genetic therapies for Huntington's disease. Clin. Sci. 110 (2006) 73-88
82. Hantraye P., Riche D., Maziere M., and Isacson O. A primate model of Huntington's disease: behavioral and anatomical studies of unilateral excitotoxic lesions of the caudate-putamen in the baboon. Exp. Neurol. 108 (1990) 91-104
83. Hansson O., Guatteo E., Mercuri N.B., Bernardi G., Li X.-J., Castilho R.F., and Brundin P. Resistance to NMDA toxicity correlates with appearance of nuclear inclusions, behavioural deficits and changes in calcium homeostasis in mice transgenic for exon 1 of the huntingtin gene. Eur. J. Neurosci. 14 (2001) 1492-1504
84. Hardingham G.E., and Bading H. The Yin and Yang of NMDA receptor signaling. Trends Neurosci. 26 (2003) 81-89
85. Hardingham G.E., Fukunaga Y., and Bading H. Extrasynaptic NMDARs oppose synaptic NMDARs by triggering CREB shut-off and cell death pathways. Nat. Neurosci. 5 (2002) 405-414
86. Harjes P., and Wanker E.E. The hunt for huntingtin function: interaction partners tell many different stories. Trends Biochem. Sci. 28 (2003) 425-433
87. Harper, P.S., 1991. In: Harper, P.S. (Ed.), Huntington's Disease. WB Saunders Co. Ltd., London.
88. Harris A.S., Denovan-Wright E.M., Hamilton L.C., and Robertson H.A. Protein kinase C beta II mRNA levels decrease in the striatum and cortex of transgenic Huntington's disease mice. J. Psychiatry Neurosci. 26 (2001) 117-122
89. Hebb C. CNS at the cellular level: identity of transmitter agents. Annu. Rev. Physiol. 32 (1970) 165-192
90. Heckmann J.M., Legg P., Sklar D., Fine J., Bryer A., and Kies B. IV amantadine improves chorea in Huntington's disease: an acute randomized, controlled study. Neurology 63 (2004) 597-598
91. Hodgson J.G., Agopyan N., Gutekunst C.A., Leavitt B.R., LePiane F., Singaraja R., Smith D.J., Bissada N., McCutcheon K., Nasir J., Jamot L., Li X.J., Stevens M.E., Rosemond E., Roder J.C., Phillips A.G., Rubin E.M., Hersch S.M., and Hayden M.R. A YAC mouse model for Huntington's disease with full-length mutant huntingtin, cytoplasmic toxicity, and selective striatal neurodegeneration. Neuron 23 (1999) 181-192
92. Hollmann M., Boulter J., Maron C., Beasley L., Sullivan J., Pecht G., and Heinemann S. Zinc potentiates agonist-induced currents at certain splice variants of the NMDA receptor. Neuron 10 (1993) 943-954
93. Huntington's Disease Collaborative Research Group. A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes. Cell 72 (1993) 971-983
94. Huntington Study Group. A randomized, placebo-controlled trial of coenzyme Q10 and remacemide in Huntington's disease. Neurology 57 (2001) 397-404
95. Huntington Study Group. Dosage effects of riluzole in Huntington's disease: a multicenter placebo-controlled study. Neurology 61 (2003) 1551-1556
96. Huntington Study Group. Minocycline safety and tolerability in Huntington disease. Neurology 63 (2004) 547-549
97. Ishii T., Moriyoshi K., Sugihara H., Sakurada K., Kadotani H., Yokoi M., Akazawa C., Shigemoto R., Mizuno N., Masu M., et al. Molecular characterization of the family of the N-methyl-d-aspartate receptor subunits. J. Biol. Chem. 268 (1993) 2836-2843
98. Jarabek B.R., Yasuda R.P., and Wolfe B.B. Regulation of proteins affecting NMDA receptor-induced excitotoxicity in a Huntington's mouse model. Brain 127 (2004) 505-516
99. Jason G.W., Suchowersky O., Pajurkova E.M., Graham L., Klimek M.L., Garber A.T., and Poirier-Heine D. Cognitive manifestations of Huntington disease in relation to genetic structure and clinical onset. Arch. Neurol. 54 (1997) 1081-1088
100. Jenkins B.G., Koroshetz W.J., Beal M.F., and Rosen B.R. Evidence for impairment of energy metabolism in vivo in Huntington's disease using localized 1H NMR spectroscopy. Neurology 43 (1993) 2689-2695
101. Kehoe P., Krawczak M., Harper P.S., Owen M.J., and Jones A.L. Age of onset in Huntington disease: sex specific influence of apolipoprotein E genotype and normal CAG repeat length. J. Med. Genet. 36 (1999) 108-111
102. Kew J.N., and Kemp J.A. Ionotropic and metabotropic glutamate receptor structure and pharmacology. Psychopharmacology (Berl.) 179 (2005) 4-29
103. Kieburtz K., Feigin A., McDermott M., Como P., Abwender D., Zimmerman C., Hickey C., Orme C., Claude K., Sotack J., Greenamyre J.T., Dunn C., and Shoulson I. A controlled trial of remacemide hydrochloride in Huntington's disease. Mov. Disord. 11 (1996) 273-277
104. Kim E., and Sheng M. PDZ domain proteins of synapses. Nat. Rev. Neurosci. 5 (2004) 771-781
105. Klapstein G.J., Fisher R.S., Zanjani H., Cepeda C., Jokel E.S., Chesselet M.F., and Levine M.S. Electrophysiological and morphological changes in striatal spiny neurons in R6/2 Huntington's disease transgenic mice. J. Neurophysiol. 86 (2001) 2667-2677
106. Kornau H.C., Schenker L.T., Kennedy M.B., and Seeburg P.H. Domain interaction between NMDA receptor subunits and the postsynaptic density protein PSD-95. Science 269 (1995) 1737-1740
107. Koroshetz W.J., Jenkins B.G., Rosen B.R., and Beal M.F. Energy metabolism defects in Huntington's disease and effects of coenzyme Q10. Ann. Neurol. 41 (1997) 160-165
108. Kremer B., Clark C.M., Almqvist E.W., Raymond L.A., Graf P., Jacova C., Mezei M., Hardy M.A., Snow B., Martin W., and Hayden M.R. Influence of lamotrigine on progression of early Huntington disease: a randomized clinical trial. Neurology 53 (1999) 1000-1011
109. Kuppenbender K.D., Standaert D.G., Feuerstein T.J., Penney Jr. J.B., Young A.B., and Landwehrmeyer G.B. Expression of NMDA receptor subunit mRNAs in neurochemically identified projection and interneurons in the human striataum. J. Comp. Neurol. 419 (2000) 407-421
110. Laforet G.A., Sapp E., Chase K., McIntyre C., Boyce F.M., Campbell M., Cadigan B.A., Warzecki L., Tagle D.A., Reddy P.H., Cepeda C., Calvert C.R., Jokel E.S., Klapstein G.J., Ariano M.A., Levine M.S., DiFiglia M., and Aronin N. Changes in cortical and striatal neurons predict behavioral and electrophysiological abnormalities in a transgenic murine model of Huntington's disease. J. Neurosci. 21 (2001) 9112-9123
111. Lan J.Y., Skeberdis V.A., Jover T., Grooms S.Y., Lin Y., Araneda R.C., Zheng X., Bennett M.V., and Zukin R.S. Protein kinase C modulates NMDA receptor trafficking and gating. Nat. Neurosci. 4 (2001) 382-390
112. Landwehrmeyer G.B., Standaert D.G., Testa C.M., Penney Jr. J.B., and Young A.B. NMDA receptor subunit mRNA expression by projection neurons and interneurons in rat striatum. J. Neurosci. 15 (1995) 5297-5307
113. Laube B., Kuhse J., and Betz H. Evidence for a tetrameric structure of recombinant NMDA receptors. J. Neurosci. 18 (1998) 2954-2961
114. Laurie D.J., Bartke I., Schoepfer R., Naujoks K., and Seeburg P.H. Regional, developmental and interspecies expression of the four NMDAR2 subunits, examined using monoclonal antibodies. Brain Res. Mol. Brain Res. 51 (1997) 23-32
115. Lawrence A.D., Sahakian B.J., Hodges J.R., Rosser A.E., Lange K.W., and Robbins T.W. Executive and mnemonic functions in early Huntington's disease. Brain 119 (1996) 1633-1645
116. Lawrence A.D., Hodges J.R., Rosser A.E., Kershaw A., French-Constant C., Rubinsztein D.C., Robbins T.W., and Sahakian B.J. Evidence for specific cognitive deficits in preclinical Huntington's disease. Brain 121 (1998) 1329-1341
117. Leenders K.L., Frackowiak R.S., Quinn N., and Marsden C.D. Brain energy metabolism and dopaminergic function in Huntington's disease measured in vivo using positron emission tomography. Mov. Disord. 1 (1986) 69-77
118. Leonard A.S., and Hell J.W. Cyclic AMP-dependent protein kinase and protein kinase C phosphorylate N-methyl-d-aspartate receptors at different sites. J. Biol. Chem. 272 (1997) 12107-12115
119. Levine M.S., Klapstein G.J., Koppel A., Gruen E., Cepeda C., Vargas M.E., Jokel E.S., Carpenter E.M., Zanjani H., Hurst R.S., Efstratiadis A., Zeitlin S., and Chesselet M.-F. Enhanced sensitivity to N-methyl-d-aspartate receptor activation in transgenic and knockin mouse models of Huntington's disease. J. Neurosci. Res. 58 (1999) 515-532
120. Li B., Chen N., Luo T., Otsu Y., Murphy T.H., and Raymond L.A. Differential regulation of synaptic and extra-synaptic NMDA receptors. Nat. Neurosci. 5 (2002) 833-834
121. Li H., Li S.H., Yu Z.X., Shelbourne P., and Li X.J. Huntingtin aggregate-associated axonal degeneration is an early pathological event in Huntington's disease mice. J. Neurosci. 21 (2001) 8473-8481
122. Li J.H., Wang Y.H., Wolfe B.B., Krueger K.E., Corsi L., Stocca G., and Vicini S. Developmental changes in localization of NMDA receptor subunits in primary cultures of cortical neurons. Eur. J. Neurosci. 10 (1998) 1704-1715
123. Li L., Fan M., Icton C.D., Chen N., Leavitt B.R., Hayden M.R., Murphy T.H., and Raymond L.A. Role of NR2B-type NMDA receptors in selective neurodegeneration in Huntington disease. Neurobiol. Aging 24 (2003) 1113-1121
124. Li L., Murphy T.H., Hayden M.R., and Raymond L.A. Enhanced striatal NR2B-containing N-methyl-d-aspartate receptor-mediated synaptic currents in a mouse model of Huntington disease. J. Neurophysiol. 92 (2004) 2738-2746
125. Li S.H., and Li X.J. Huntingtin-protein interactions and the pathogenesis of Huntington's disease. Trends Genet. 20 (2004) 146-154
126. Lievens J.C., Woodman B., Mahal A., Spasic-Boscovic O., Samuel D., Kerkerian-Le Goff L., and Bates G.P. Impaired glutamate uptake in the R6 Huntington's disease transgenic mice. Neurobiol. Dis. 8 (2001) 807-821
127. Lin C.H., Tallaksen-Greene S., Chien W.M., Cearley J.A., Jackson W.S., Crouse A.B., Ren S., Li X.J., and Albin R.L. Neurological abnormalities in a knock-in mouse model of Huntington's disease. Hum. Mol. Genet. 10 (2001) 137-144
128. Liu L., Wong T.P., Pozza M.F., Lingenhoehl K., Wang Y., Sheng M., Auberson Y.P., and Wang Y.T. Role of NMDA receptor subtypes in governing the direction of hippocampal synaptic plasticity. Science 304 (2004) 1021-1024
129. Loftis J.M., and Janowsky A. The N-methyl-d-aspartate receptor subunit NR2B: localization, functional properties, regulation, and clinical implications. Pharmacol. Ther. 97 (2003) 55-85
130. Lucas D.R., and Newhouse J.P. The toxic effect of sodium l-glutamate on the inner layers of the retina. A.M.A. Arch. Ophthalmol. 58 (1957) 193-201
131. Lucetti C., Del Dotto P., Gambaccini G., Dell'Agnello G., Bernardini S., Rossi G., Murri L., and Bonuccelli U. IV amantadine improves chorera in Huntington's disease: an acute randomized, controlled study. Neurology 60 (2003) 1995-1997
132. Luthi-Carter R., Strand A., Peters N.L., Solano S.M., Hollingsworth Z.R., Menon A.S., Frey A.S., Spektor B.S., Penney E.B., Schilling G., Ross C.A., Borchelt D.R., Tapscott S.J., Young A.B., Cha J.-H.J., and Olson J.M. Decreased expression of striatal signaling genes in a mouse model of Huntington's disease. Hum. Mol. Genet. 9 (2000) 1259-1271
133. Luthi-Carter R., Apostol B.L., Dunah A.W., DeJohn M.M., Farrell L.A., Bates G.P., Young A.B., Standaert D.G., Thompson L.M., and Cha J.-H.J. Complex alteration of NMDA receptors in transgenic Huntington's disease mouse brain: analysis of mRNA and protein expression, plasma membrane association, interacting proteins, and phosphorylation. Neurobiol. Dis. 14 (2003) 624-636
134. Mangiarini L., Sathasivam K., Seller M., Cozens B., Harper A., Hetherington C., Lawton M., Trottier Y., Lehrach H., Davies S.W., and Bates G.P. Exon 1 of the HD gene with an expanded CAG repeat is sufficient to cause a progressive neurological phenotype in transgenic mice. Cell 87 (1996) 493-506
135. Maren S., and Baudry M. Properties and mechanisms of long-term synaptic plasticity in the mammalian brain: relationships to learning and memory. Neurobiol. Learn. Mem. 63 (1995) 1-18
136. Martinez-Vicente M., Sovak G., and Cuervo A.M. Protein degradation and aging. Exp. Gerontol. 40 (2005) 622-633
137. Massey P.V., Johnson B.E., Moult P.R., Auberson Y.P., Brown M.W., Molnar E., Collingridge G.L., and Bashir Z.I. Differential roles of NR2A and NR2B-containing NMDA receptors in cortical long-term potentiation and long-term depression. J. Neurosci. 24 (2004) 7821-7828
138. 2+ of NMDA responses in spinal cord neurones. Nature 309 (1984) 261-263
139. Mazarakis N.K., Cybulska-Klosowicz A., Grote H., Pang T., Van Dellen A., Kossut M., Blakemore C., and Hannan A.J. Deficits in experience-dependent cortical plasticity and sensory-discrimination learning in presymptomatic Huntington's disease mice. J. Neurosci. 25 (2005) 3059-3066
140. McBain C.J., and Mayer M.L. N-methyl-d-aspartic acid receptor structure and function. Physiol. Rev. 74 (1994) 723-760
141. McGeer E.G., and McGeer P.L. Duplication of biochemical changes of Huntington's chorea by intrastriatal injections of glutamic and kainic acids. Nature 263 (1976) 517-519
142. McGeer E.G., and McGeer P.L. Some factors influencing the neurotoxicity of intrastriatal injections of kainic acid. Neurochem. Res. 3 (1978) 501-517
143. McIlhinney R.A., Le Bourdelles B., Molnar E., Tricaud N., Streit P., and Whiting P.J. Assembly intracellular targeting and cell surface expression of the human N-methyl-d-aspartate receptor subunits NR1a and NR2A in transfected cells. Neuropharmacology 37 (1998) 1355-1367
144. Menalled L.B., and Chesselet M.F. Mouse models of Huntington's disease. Trends Pharmacol. Sci. 23 (2002) 32-39
145. Michaelis E.K. Molecular biology of glutamate receptors in the central nervous system and their role in excitotoxicity, oxidative stress and aging. Prog. Neurobiol. 54 (1998) 369-415
146. Milnerwood A.J., Cummings D.M., Dallerac G.M., Brown J.Y., Vatsavayai S.C., Hirst M.C., Rezaie P., and Murphy K.P. Early development of aberrant synaptic plasticity in a mouse model of Huntington's disease. Hum. Mol. Genet. 15 (2006) 1690-1703
147. Milnerwood A.J., and Raymond L.A. Synaptic abnormalities associated with Huntington's disease. In: Dityatev A., and El-Husseini A. (Eds). Molecular Mechanisms of Synaptogenesis (2006), Springer, New York, U.S.A. 457-472
148. Monyer H., Sprengel R., Schoepfer R., Herb A., Higuchi M., Lomeli H., Burnashev N., Sakmann B., and Seeburg P.H. Heteromeric NMDA receptors: molecular and functional distinction of subtypes. Science 256 (1992) 1217-1221
149. Monyer H., Burnashev N., Laurie D.J., Sakmann B., and Seeburg P.H. Developmental and regional expression in the rat brain and functional properties of four NMDA receptors. Neuron 12 (1994) 529-540
150. Morishita W., Lu W., Smith G.B., Nicoll R.A., Bear M.F., and Malenka R.C. Activation of NR2B-containing NMDA receptors is not required for NMDA receptor-dependent long-term depression. Neuropharmacology (2006) (Epub ahead of print)
151. Murman D.L., Giordani B., Mellow A.M., Johanns J.R., Little R.J., Hariharan M., and Foster N.L. Cognitive, behavioral, and motor effects of the NMDA antagonist ketamine in Huntington's disease. Neurology 49 (1997) 153-161
152. Murphy K.P., Carter R.J., Lione L.A., Mangiarini L., Mahal A., Bates G.P., Dunnett S.B., and Morton A.J. Abnormal synaptic plasticity and impaired spatial cognition in mice transgenic for exon 1 of the human Huntington's disease mutation. J. Neurosci. 20 (2000) 5115-5123
153. Nicholls D.G., and Ward M.W. Mitochondrial membrane potential and neuronal glutamate excitotoxicity: mortality and millivolts. Trends Neurosci. 23 (2000) 166-174
154. Nicholson D.W., and Thornberry N.A. Caspases, killer proteases. Trends Biochem. Sci. 22 (1997) 299-306
155. Nowak L., Bregestovski P., Ascher P., Herbet A., and Prochiantz A. Magnesium gates glutamate-activated channels in mouse central neurones. Nature 307 (1984) 462-465
156. 2+ handling in Huntington's disease striatal cells: effect of histone deacetylase inhibitors. Neurobiol. Dis. 26 (2006) 11174-11186
157. Orlando L.R., Alsdorf S.A., Penney Jr. J.B., and Young A.B. The role of group I and group II metabotropic glutamate receptors in modulation of striatal NMDA and quinolinic acid toxicity. Exp. Neurol. 167 (2001) 196-204
158. Orrenius S. Mitochondrial regulation of apoptotic cell death. Toxicol. Lett. 149 (2004) 19-23
159. Ozawa S., Kamiya H., and Tsuzuki K. Glutamate receptors in the mammalian central nervous system. Prog. Neurobiol. 54 (1998) 581-618
160. Panov A.V., Gutekunst C.A., Leavitt B.R., Hayden M.R., Burke J.R., Strittmatter W.J., and Greenamyre J.T. Early mitochondrial calcium defects in Huntington's disease are a direct effect of polyglutamines. Nat. Neurosci. 5 (2002) 731-736
161. Paulsen J.S., et al. Clinical markers of early disease in persons near onset of Huntington's disease. Neurology 57 (2001) 658-662
162. Peng T., and Greenamyre J.T. Privileged access to mitochondria of calcium influx through N-methyl-d-aspartate receptors. Mol. Pharmacol. 53 (1998) 974-980
163. Petersen A., Chase K., Puschban Z., DiFiglia M., Brundin P., and Aronin N. Maintenance of susceptibility to neurodegeneration following intrastriatal injections of quinolinic acid in a new transgenic mouse model of Huntington's disease. Exp. Neurol. 175 (2002) 297-300
164. Picconi B., Passino E., Sgobio C., Bonsi P., Barone I., Ghiglieri V., Pisani A., Bernardi G., Ammassari-Teule M., and Calabresi P. Plastic and behavioral abnormalities in experimental Huntington's disease: a crucial role for cholinergic interneurons. Neurobiol. Dis. 22 (2006) 143-152
165. Prybylowski K., and Wenthold R.J. N-methyl-D-aspartate receptors: subunit assembly and trafficking to the synapse. J. Biol. Chem. 279 (2004) 9673-9676
166. Puri B.K., Leavitt B.R., Hayden M.R., Ross C.A., Rosenblatt A., Greenamyre J.T., Hersch S., Vaddadi K.S., Sword A., Horrobin D.F., Manku M., and Murck H. Ethyl-EPA in Huntington disease: a double-blind, randomized, placebo-controlled trial. Neurology 65 (2005) 286-292
167. Raman I.M., Tong G., and Jahr C.E. Beta-adrenergic regulation of synaptic NMDA receptors by cAMP-dependent protein kinase. Neuron 16 (1996) 415-421
168. Reddy P.H., Charles V., Williams M., Miller G., Whetsell Jr. W.O., and Tagle D.A. Transgenic mice expressing mutated full-length HD cDNA: a paradigm for locomotor changes and selective neuronal loss in Huntington's disease. Philos. Trans. R. Soc. Lond. B 354 (1999) 1035-1045
169. Reynolds I.J., and Hastings T.G. Glutamate induces the production of reactive oxygen species in cultured forebrain neurons following NMDA receptor activation. J. Neurosci. 15 (1995) 3318-3327
170. Rigby M., Le Bourdelles B., Heavens R.P., Kelly S., Smith D., Butler A., Hammans R., Hills R., Xuereb J.H., Hill R.G., Whiting P.J., and Sirinathsinghji D.J. The messenger RNAs for the N-methyl-d-aspartate receptor subunits show region-specific expression of different subunit composition in the human brain. Neuroscience 73 (1996) 429-447
171. Roche K.W., Standley S., McCallum J., Dune Ly C., Ehlers M.D., and Wenthold R.J. Molecular determinants of NMDA receptor internalization. Nat. Neurosci. 4 (2001) 794-802
172. Ross C.A. Polyglutamine pathogenesis: emergence of unifying mechanisms for Huntington's disease and related disorders. Neuron 35 (2002) 819-822
173. Rothman S.M., and Olney J.W. Excitotoxicity and the NMDA receptor-still lethal after 8 years. Trends Neurosci. 18 (1995) 57-58
174. Rubinsztein D.C. Lessons from animal models of Huntington's disease. Trends Genet. 18 (2002) 202-209
175. Saft C., Zange J., Andrich J., Muller K., Lindenberg K., Landwehrmeyer B., Vorgerd M., Kraus P.H., Przuntek H., and Schols L. Mitochondrial impairment in patients and asymptomatic mutation carriers of Huntington's disease. Mov. Disord. 20 (2005) 674-679
176. Salter M.W., and Kalia L.V. Src kinases: a hub for NMDA receptor regulation. Nat. Rev. Neurosci. 5 (2004) 317-328
177. Sanberg P.R., Calderon S.F., Giordano M., Tew J.M., and Norman A.B. The quinolinic acid model of Huntington's disease: locomotor abnormalities. Exp. Neurol. 105 (1989) 45-53
178. Sanchez I., Xu C.J., Juo P., Kakizaka A., Blenis J., and Yuan J. Caspase-8 is required for cell death induced by expanded polyglutamine repeats. Neuron 22 (1999) 623-633
179. Sans N., Petralia R.S., Wang Y.X., Blahos II J., Hell J.W., and Wenthold R.J. A developmental change in NMDA receptor-associated proteins at hippocampal synapses. J. Neurosci. 20 (2000) 1260-1271
180. Sattler R., Charlton M.P., Hafner M., and Tymianski M. Distinct influx pathways, not calcium load, determine neuronal vulnerability to calcium neurotoxicity. J. Neurochem. 71 (1998) 2349-2364
181. Sattler R., Xiong Z., Lu W.Y., Hafner M., MacDonald J.F., and Tymianski M. Specific coupling of NMDA receptor activation to nitric oxide neurotoxicity by PSD-95 protein. Science 284 (1999) 1845-1848
182. Sawa A., Wiegand G.W., Cooper J., Margolis R.L., Sharp A.H., Lawler Jr. J.F., Greenamyre J.T., Snyder S.H., and Ross C.A. Increased apoptosis of Huntington disease lymphoblasts associated with repeat length-dependent mitochondrial depolarization. Nat. Med. 5 (1999) 1194-1198
183. Schilling G., Becher M.W., Sharp A.H., Jinnah H.A., Duan K., Kotzuk J.A., Slunt H.H., Ratovitski T., Cooper J.K., Jenkins N.A., Copeland N.G., Price D.L., Ross C.A., and Borchelt D.R. Intranuclear inclusions and neuritic aggregates in transgenic mice expressing a mutant N-terminal fragment of huntingtin. Hum. Mol. Genet. 8 (1999) 397-407
184. Schwarcz R., Bennett Jr. J.P., and Coyle Jr. J.T. Loss of striatal serotonin synaptic receptor binding induced by kainic acid lesions: correlations with Huntington's disease. J. Neurochem. 4 (1977) 867-869
185. Schwarcz R., Foster A.C., French E.D., Whetsell Jr. W.O., and Kohler C. Excitotoxic models for neurodegenerative disorders. Life Sci. 35 (1984) 19-32
186. Scott D.B., Blanpied T.A., Swanson G.T., Zhang C., and Ehlers M.D. An NMDA receptor ER retention signal regulated by phosphorylation and alternative splicing. J. Neurosci. 21 (2001) 3063-3072
187. Scott D.B., Blanpied T.A., and Ehlers M.D. Coordinated PKA and PKC phosphorylation suppresses RXR-mediated ER retention and regulates the surface delivery of NMDA receptors. Neuropharmacology 45 (2003) 755-767
188. Seong I.S., Ivanova E., Lee J.-M., Choo Y.S., Fossale E., Anderson M., Gusella J.F., Laramie J.M., Myers R.H., Lesort M., and MacDonald M.E. HD CAG repeat implicates a dominant property of huntingtin in mitochondrial energy metabolism. Hum. Mol. Genet. 14 (2005) 2871-2880
189. Shehadeh J., Fernandes H.B., Zeron Mullins M.M., Graham R.K., Leavitt B.R., Hayden M.R., and Raymond L.A. Striatal neuronal apoptosis is preferentially enhanced by NMDA receptor activation in YAC transgenic mouse model of Huntington disease. Neurobiol. Dis. 21 (2006) 392-403
190. Shelbourne P.F., Killeen N., Hevner R.F., Johnston H.M., Tecott L., Lewandoski M., Ennis M., Ramirez L., Li Z., Iannicola C., Littman D.R., and Myers R.M. A Huntington's disease CAG expansion at the murine Hdh locus is unstable and associated with behavioural abnormalities in mice. Hum. Mol. Genet. 8 (1999) 763-774
191. Shin J.Y., Fang Z.H., Yu Z.X., Wang C.E., Li S.H., and Li X.J. Expression of mutant huntingtin in glial cells contributes to neuronal excitotoxicity. J. Cell Biol. 171 (2005) 1001-1012
192. Slow E.J., van Raamsdonk J., Rogers D., Coleman S.H., Graham R.K., Deng Y., Oh R., Bissada N., Hossain S.M., Yang Y.Z., Li X.J., Simpson E.M., Gutekunst C.A., Leavitt B.R., and Hayden M.R. Selective striatal neuronal loss in a YAC128 mouse model of Huntington disease. Hum. Mol. Genet. 12 (2003) 1555-1567
193. Slow E.J., Graham R.K., Osmand A.P., Devon R.S., Lu G., Deng Y., Pearson J., Vaid K., Bissada N., Wetzel R., Leavitt B.R., and Hayden M.R. Absence of behavioral abnormalities and neurodegeneration in vivo despite widespread neuronal huntingtin inclusions. Proc. Natl. Acad. Sci. U.S.A. 102 (2005) 11402-11407
194. Song C., Zhang Y., Parsons C.G., and Liu Y.F. Expression of polyglutamine-expanded huntingtin induces tyrosine phosphorylation of N-methyl-d-aspartate receptors. J. Biol. Chem. 278 (2003) 33364-33369
195. Soriano F.X., Papadia S., Hofmann F., Hardingham N.R., Bading H., and Hardingham G.E. Preconditioning doses of NMDA promote neuroprotection by enhancing neuronal excitability. J. Neurosci. 26 (2006) 4509-4518
196. Stack E.C., Smith K.M., Ryu H., Cormier K., Chen M., Hagerty S.W., Del Signore S.J., Cudkowicz M.E., Friedlander R.M., and Ferrante R.J. Combination therapy using minocycline and coenzyme Q10 in R6/2 transgenic Huntington's disease mice. Biochim. Biophys. Acta 1762 (2006) 373-380
197. Stahl W.L., and Swanson P.D. Biochemical abnormalities in Huntington's chorea brains. Neurology 24 (1974) 813-819
198. Standaert D.G., Friberg I.K., Landwehrmeyer G.B., Young A.B., and Penney Jr. J.B. Expression of NMDA glutamate receptor subunit mRNAs in neurochemically identified projection and interneurons in the striatum of the rat. Brain Res. Mol. Brain Res. 64 (1999) 11-23
199. Starling A.J., Andre V.M., Cepeda C., de Lima M., Chandler S.H., and Levine M.S. Alterations in N-methyl-d-aspartate receptor sensitivity and magnesium blockade occur early in development in the R6/2 mouse model of Huntington's disease. J. Neurosci. Res. 82 (2005) 377-386
200. Stocca G., and Vicini S. Increased contribution of NR2A subunit to synaptic NMDA receptors in developing rat cortical neurons. J. Physiol. 507 (1998) 13-24
201. Stout A.K., Raphael H.M., Kanterewicz B.I., Klann E., and Reynolds I.J. Glutamate-induced neuron death requires mitochondrial calcium uptake. Nat. Neurosci. 1 (1998) 366-373
202. Sugars K.L., and Rubinsztein D.C. Transcriptional abnormalities in Huntington disease. Trends Genet. 19 (2003) 233-238
203. Sun Y., Savanenin A., Reddy P.H., and Liu Y.F. Polyglutamine-expanded huntingtin promotes sensitization of N-methyl-d-aspartate receptors via post-synaptic density 95. J. Biol. Chem. 276 (2001) 24713-24718
204. Tabrizi S.J., Cleeter M.W., Xuereb J., Taanman J.W., Cooper J.M., and Schapira A.H. Biochemical abnormalities and excitotoxicity in Huntington's disease brain. Ann. Neurol. 45 (1999) 25-32
205. Tabrizi S.J., Blamire A.M., Manners D.N., Rajagopalan B., Styles P., Schapira A.H., and Warner T.T. Creatine therapy for Huntington's disease: clinical and MRS findings in a 1-year pilot study. Neurology 61 (2003) 141-142
206. Tabrizi S.J., Blamire A.M., Manners D.N., Rajagopalan B., Styles P., Schapira A.H., and Warner T.T. High-dose creatine therapy for Huntington disease: a 2-year clinical and MRS study. Neurology 64 (2005) 1655-1656
207. Tang T.-S., Tu H., Chan E.Y.W., Maximov A., Wang Z., Wellington C.L., Hayden M.R., and Bezprozvanny I. Huntingtin and huntingtin-associated protein 1 influence neuronal calcium signaling mediated by inositol-(1,4,5) triphosphate receptor type 1. Neuron 39 (2003) 227-239
208. 2+ release in primary culture of striatal medium spiny neurons. Eur. J. Neurosci. 20 (2004) 1779-1787
209. 2+ signaling and apoptosis of medium spiny neurons in Huntington's disease. Proc. Natl. Acad. Sci. U.S.A. 102 (2005) 2602-2607
210. Thomas C.G., Miller A.J., and Westbrook G.L. Synaptic and extrasynaptic NMDA receptor NR2 subunits in cultured hippocampal neurons. J. Neurophysiol. 95 (2006) 1727-1734
211. Thomas M., Ashizawa T., and Jankovic J. Minocycline in Huntington's disease: a pilot study. Mov. Disord. 19 (2004) 692-695
212. Tingley W.G., Ehlers M.D., Kameyama K., Doherty C., Ptak J.B., Riley C.T., and Huganir R.L. Characterization of protein kinase A and protein kinase C phosphorylatioin of the N-methyl-d-aspartate receptor NR1 subunit using phosphorylation site-specific antibodies. J. Biol. Chem. 272 (1997) 5157-5166
213. Tobin A.J., and Signer E.R. Huntington's disease: the challenge for cell biologists. Trends Cell Biol. 10 (2000) 531-536
214. Tovar K.R., and Westbrook G.L. The incorporation of NMDA receptors with a distinct subunit composition at nascent hippocampal synapses in vitro. J. Neurosci. 19 (1999) 4180-4188
215. Trettel F., Rigamonti D., Hilditch-Maguire P., Wheeler V.C., Sharp A.H., Persichetti F., Cattaneo E., and MacDonald M.E. Dominant phenotypes produced by the HD mutation in STHdh(Q111) striatal cells. Hum. Mol. Genet. 9 (2000) 2799-2809
216. Trottier Y., Devys D., Imbert G., Saudou F., An I., Lutz Y., Weber C., Agid Y., Hirsch E.C., and Mandel J.L. Cellular localization of the Huntington's disease protein and discrimination of the normal and mutated form. Nat. Genet. 10 (1995) 104-110
217. Usdin M.T., Shelbourne P.F., Myers R.M., and Madison D.V. Impaired synaptic plasticity in mice carrying the Huntington's disease mutation. Hum. Mol. Genet. 8 (1999) 839-846
218. Van Raamsdonk J.M., Pearson J., Rogers D.A., Bissada N., Vogl A.W., Hayden M.R., and Leavitt B.R. Loss of wild-type huntingtin influences motor dysfunction and survival in the YAC128 mouse model of Huntington disease. Hum. Mol. Genet. 14 (2005) 1379-1392
219. Verhagen Metman L., Morris M.J., Farmer C., Gillespie M., Mosby K., Wuu J., and Chase T.N. Huntington's disease: a randomized, controlled trial using the NMDA-antagonist amantadine. Neurology 59 (2002) 694-699
220. Vicini S., Wang J.F., Li J.H., Zhu W.J., Wang Y.H., Luo J.H., Wolfe B.B., and Grayson D.R. Functional and pharmacological differences between recombinant N-methyl-d-aspartate receptors. J. Neurophysiol. 79 (1998) 555-566
221. Vissel B., Krupp J.J., Heinemann S.F., and Westbrook G.L. A use-dependent tyrosine dephosphorylation of NMDA receptors is independent of ion flux. Nat. Neurosci. 4 (2001) 587-596
222. Von Horsten S., Schmitt I., Nguyen H.P., Holzmann C., Schmidt T., Walther T., Bader M., Pabst R., Kobbe P., Krotova J., Stiller D., Kask A., Vaarmann A., Rathke-Hartlieb S., Schulz J.B., Grasshoff U., Bauer I., Vieira-Saecker A.M., Paul M., Jones L., Lindenberg K.S., Landwehrmeyer B., Bauer A., Li X.J., and Riess O. Transgenic rat model of Huntington's disease. Hum. Mol. Genet. 12 (2003) 617-624
223. Vonsattel J.P., and DiFiglia M. Huntington disease. J. Neuropathol. Exp. Neurol. 57 (1998) 369-384
224. Vonsattel J.P., Myers R.H., Stevens T.J., Ferrante R.J., Bird E.D., and Richardson Jr. E.P. Neuropathological classification of Huntington's disease. J. Neuropathol. Exp. Neurol. 44 (1985) 559-577
225. Wang Y.T., and Salter M.W. Regulation of NMDA receptors by tyrosine kinases and phosphatases. Nature 369 (1994) 233-235
226. 2+] and is prevented by ATP in rat spinal dorsal horn neurons. Neurosci. Lett. 157 (1993) 183-186
227. Wang Y.T., Yu X.M., and Salter M.W. Ca(2+)-independent reduction of N-methyl-d-aspartate channel activity by protein tyrosine phosphatase. Proc. Natl. Acad. Sci. U.S.A. 93 (1996) 1721-1725
228. Waxman E.A., and Lynch D.R. N-Methyl-d-aspartate receptor subtypes: multiple roles in excitotoxicity and neurological disease. Neuroscientist 11 (2005) 37-49
229. Wellington C.L., Ellerby L.M., Hackam A.S., Margolis R.L., Trifiro M.A., Singaraja R., McCutcheon K., Salvesen G.S., Propp S.S., Bromm M., Rowland K.J., Zhang T., Rasper D., Roy S., Thornberry N., Pinsky L., Kakizuka A., Ross C.A., Nicholson D.W., Bredesen D.E., and Hayden M.R. Caspase cleavage of gene products associated with triplet expansion disorders generates truncated fragments containing the polyglutamine tract. J. Biol. Chem. 273 (1998) 9158-9167
230. Wellington C.L., Singaraja R., Ellerby L., Savill J., Roy S., Leavitt B., Cattaneo E., Hackam A., Sharp A., Thornberry N., Nicholson D.W., Bredesen D.E., and Hayden M.R. Inhibiting caspase cleavage of huntingtin reduces toxicity and aggregate formation in neuronal and non-neuronal cells. J. Biol. Chem. 275 (2000) 19831-19838
231. Wellington C.L., Ellerby L.M., Gutekunst C.-A., Rogers D., Warby S., Graham R.K., Loubser O., van Raamsdonk J., Singaraja R., Yang Y.-Z., Gafni J., Bredesen D., Hersch S.M., Leavitt B.R., Roy S., Nicholson D.W., and Hayden M.R. Caspase cleavage of mutant huntingtin precedes neurodegeneration in Huntington's disease. J. Neurosci. 22 (2002) 7862-7872
232. Westphal R.S., Tavalin S.J., Lin J.W., Alto N.M., Fraser I.D., Langeberg L.K., Sheng M., and Scott J.D. Regulation of NMDA receptors by an associated phosphatase-kinase signaling complex. Science 285 (1999) 93-96
233. Wheeler V.C., White J.K., Gutekunst C.A., Vrbanac V., Weaver M., Li X.J., Li S.H., Yi H., Vonsattel J.P., Gusella J.F., Hersch S., Auerbach W., Joyner A.L., and MacDonald M.E. Long glutamine tracts cause nuclear localization of a novel form of huntingtin in medium spiny striatal neurons in HdhQ92 and HdhQ111 knock-in mice. Hum. Mol. Genet. 9 (2000) 503-513
234. White R.J., and Reynolds I.J. Mitochondrial depolarization in glutamate-stimulated neurons: an early signal specific to excitotoxin exposure. J. Neurosci. 16 (1996) 5688-5697
235. Wüllner U., Young A.B., Penney J.B., and Beal M.F. 3-Nitropropionic acid toxicity in the striatum. J. Neurochem. 63 (1994) 1772-1781
236. Xiong Z.G., Raouf R., Lu W.Y., Wang L.Y., Orser B.A., Dudek E.M., Browning M.D., and MacDonald J.F. Regulation of N-methyl-d-aspartate receptor function by constitutively active protein kinase C. Mol. Pharmacol. 54 (1998) 1055-1063
237. Young A.B., Greenamyre J.T., Hollingsworth Z., Albin R., D'Amato C., Shoulson I., and Penney J.B. NMDA receptor losses in putamen from patients with Huntington's disease. Science 241 (1988) 981-983
238. Yu X.M., Askalan R., Keil II G.J., and Salter M.W. NMDA channel regulation by channel-associated protein tyrosine kinase Src. Science 275 (1997) 674-678
239. Zeron M.M., Chen N., Moshaver A., Lee A.T.-C., Wellington C.L., Hayden M.R., and Raymond L.A. Mutant huntingtin enhances excitotoxic cell death. Mol. Cell. Neurosci. 17 (2001) 41-53
240. Zeron M.M., Hansson O., Chen N., Wellington C.L., Leavitt B.R., Brundin P., Hayden M.R., and Raymond L.A. Increased sensitivity to N-methyl-d-aspartate receptor-mediated excitotoxicity in a mouse model of Huntington's disease. Neuron 33 (2002) 849-860
241. Zeron M.M., Fernandes H.B., Krebs C., Shehadeh J., Wellington C.L., Leavitt B.R., Baimbridge K.G., Hayden M.R., and Raymond L.A. Potentiation of NMDA receptor-mediated excitotoxicity linked with intrinsic apoptotic pathway in YAC transgenic mouse model of Huntington's disease. Mol. Cell. Neurosci. 25 (2004) 469-479
242. Zheng X., Zhang L., Wang A.P., Bennett M.V., and Zukin R.S. Protein kinase C potentiation of N-methyl-d-aspartate receptor activity is not mediated by phosphorylation of N-methyl-d-aspartate receptor subunits. Proc. Natl. Acad. Sci. U.S.A. 96 (1999) 15262-15267